Drug Profile
QL 0A6A
Alternative Names: QL-0A6ALatest Information Update: 03 Oct 2023
Price :
$50
*
At a glance
- Originator Qilu Pharmaceutical
- Class Antivirals
- Mechanism of Action Capsid protein inhibitors; Hepatitis B virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 03 Oct 2023 Discontinued - Preclinical for Hepatitis B in China (PO) (Qilu Pharmaceutical pipeline, October 2023)
- 28 Dec 2020 No recent reports of development identified for preclinical development in Hepatitis-B in China (PO)
- 11 Nov 2016 Preclinical trials in Hepatitis B in China before November 2016 (PO)